Tags

Type your tag names separated by a space and hit enter

Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis.
Med Microbiol Immunol. 2001 Nov; 190(1-2):85-7.MM

Abstract

An oral treatment for visceral and cutaneous leishmaniasis has been searched for over the last decades. An oral drug would facilitate treatment and lower costs. Oral miltefosine (Zentaris/ASTA Medica AG, Germany), an alkylphosphocholine, is under clinical development for treatment of leishmaniasis. Phase I, II and III clinical trials have been performed in visceral leishmaniasis in India; the overall response rate with 100 mg/day over 4 weeks is 96%. A first clinical trial in New World cutaneous leishmaniasis has shown a final cure rate of 94% at a dose of 150 mg/day over 3 or 4 weeks. Side effects are mainly gastrointestinal (vomiting, diarrhoea). Furthermore, transient elevation of transaminases or urea/creatinine has been observed. The clinical results suggest that miltefosine is the first oral therapy that is effective and safe in visceral and cutaneous leishmaniasis.

Authors+Show Affiliations

Zentaris/ASTA Medica AG, Frankfurt am Main, Germany.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11770118

Citation

Fischer, C, et al. "Development Status of Miltefosine as First Oral Drug in Visceral and Cutaneous Leishmaniasis." Medical Microbiology and Immunology, vol. 190, no. 1-2, 2001, pp. 85-7.
Fischer C, Voss A, Engel J. Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. Med Microbiol Immunol. 2001;190(1-2):85-7.
Fischer, C., Voss, A., & Engel, J. (2001). Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. Medical Microbiology and Immunology, 190(1-2), 85-7.
Fischer C, Voss A, Engel J. Development Status of Miltefosine as First Oral Drug in Visceral and Cutaneous Leishmaniasis. Med Microbiol Immunol. 2001;190(1-2):85-7. PubMed PMID: 11770118.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. AU - Fischer,C, AU - Voss,A, AU - Engel,J, PY - 2002/1/5/pubmed PY - 2002/7/9/medline PY - 2002/1/5/entrez SP - 85 EP - 7 JF - Medical microbiology and immunology JO - Med Microbiol Immunol VL - 190 IS - 1-2 N2 - An oral treatment for visceral and cutaneous leishmaniasis has been searched for over the last decades. An oral drug would facilitate treatment and lower costs. Oral miltefosine (Zentaris/ASTA Medica AG, Germany), an alkylphosphocholine, is under clinical development for treatment of leishmaniasis. Phase I, II and III clinical trials have been performed in visceral leishmaniasis in India; the overall response rate with 100 mg/day over 4 weeks is 96%. A first clinical trial in New World cutaneous leishmaniasis has shown a final cure rate of 94% at a dose of 150 mg/day over 3 or 4 weeks. Side effects are mainly gastrointestinal (vomiting, diarrhoea). Furthermore, transient elevation of transaminases or urea/creatinine has been observed. The clinical results suggest that miltefosine is the first oral therapy that is effective and safe in visceral and cutaneous leishmaniasis. SN - 0300-8584 UR - https://www.unboundmedicine.com/medline/citation/11770118/Development_status_of_miltefosine_as_first_oral_drug_in_visceral_and_cutaneous_leishmaniasis_ L2 - http://www.diseaseinfosearch.org/result/4166 DB - PRIME DP - Unbound Medicine ER -